Estimation of radiation absorbed doses to the red marrow in radioimmunotherapy
- Univ. of California, Sacramento, CA (United States)
Myelotoxicity is the dose-limiting factor in radioimmunotherapy. Traditional methods most commonly used to estimate the radiation adsorbed dose to the bone marrow of patients consider contribution from radionuclide in the blood and/or total body. Targeted therapies, such as radioimmunotherapy, add a third potential source for radiation to the bone marrow because the radiolabeled targeting molecules can accumulate specifically on malignant target cells infiltrating the bone marrow. A non-invasive method for estimating the radiation absorbed dose to the red marrow of patients who have received radiolabeled monoclonal antibodies (MoAb) has been developed and explored. The method depends on determining the cumulated activity in three contributing sources: (1) marrow; (2) blood; and (3) total body. The novel aspect of this method for estimating marrow radiation dose is derivation of the radiation dose for the entire red marrow from radiation dose estimates obtained by detection of cumulated activity in three lumbar vertebrae using a gamma camera. Contributions to the marrow radiation dose form marrow, blood, and total body cumulated activity were determined for patients who received an I-131 labeled MoAb, Lym-1, that reacts with malignant B-lymphocytes of chronic lymphocytic leukemia and nonHodgkin`s lymphoma. Six patients were selected for illustrative purposes because their vertebrae were readily visualized on lumbar images. 32 refs., 6 figs., 1 tab.
- Sponsoring Organization:
- USDOE
- OSTI ID:
- 381136
- Journal Information:
- Clinical Nuclear Medicine, Vol. 20, Issue 2; Other Information: PBD: Feb 1995
- Country of Publication:
- United States
- Language:
- English
Similar Records
Factors affecting the relationship between the red marrow dose and myelotoxicity in patients receiving radioimmunotherapy with {sup 131}I-labeled anti-CEA monoclonal antibodies
α-Imaging Confirmed Efficient Targeting of CD₄₅-Positive Cells After ²¹¹At-Radioimmunotherapy for Hematopoietic Cell Transplantation